A research team has made a breakthrough in epigenetic drug discovery. The researchers have successfully developed a first-in-class chemical inhibitor that precisely and selectively targets the ATAC complex, a critical cellular “switch operator” that activates tumor-promoting genes, opening a novel therapeutic avenue for non-small cell lung cancer (NSCLC).
This article was originally published on MedicalXpress.com
Almost half of all Canadians regularly take at least one nutritional supplement such as vitamins, minerals, fibre supplements, antacids and fish oils. Many of these individuals are healthy and hoping to improve general well-being or prevent chronic […]
By Daniel Zane Bryant, author of “Living with Food Allergies: A Complete Lifestyle Guide” (available on Amazon at https://www.amazon.com/dp/B0G2BcGB2K) Navigating food allergies might initially feel overwhelming, yet it presents an exciting opportunity to reimagine familiar […]
What Are Boundaries? As the word portrays, boundaries in a relationship help each person establish expectations with their partner. Boundaries can help you communicate what you are comfortable with and what you are willing to […]
© 2025 SimplyWell.ca